


OFFICIAL

IN THE CLAIMS

1. (currently amended) A compound as ~~represented by of~~ formula (I), or its ~~an~~ enantiomers or diastereoisomers thereof:



(I)

wherein:

A is a 5- or 6-membered homocyclic ring, ~~or a 5- or 6-membered heterocyclic ring containing~~
~~1 or more heteroatoms selected from N, O and S;~~

X is H and W is OH; or X and W together form a carbonyl group or an epoxide;

R¹ is H; or one or two substituents independently selected from the group consisting of:
 hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl (e.g. trifluoromethyl); or
~~-C(O)R² wherein R² is lower alkyl, aryloxy or benzyloxy;~~

Y is phenyl optionally mono- or di-substituted with R⁵ or C(O)R⁶, wherein R⁵ is lower alkyl,
 lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and R⁶ is lower
 alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being
 optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a
 heteroatom selected from N, O and S;

~~or Y is a heterocycle (Het) containing one or more heteroatom selected from N, O or S, said
 Het optionally mono- or di-substituted with R⁵ or C(O)R⁶, wherein R⁵ and R⁶ are as defined
 above; said Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring
 optionally containing a heteroatom selected from N, O and S;~~

or Y is ethylene-phenyl, said ethylene moiety being optionally mono-substituted with lower
 alkyl, wherein said phenyl ring is optionally mono- or di-substituted with R⁵ or C(O)R⁶,
 wherein R⁵ and R⁶ are as defined above; said phenyl ring being optionally fused with a
 saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected

OFFICIAL

from N, O and S;

~~or Y is ethylene-Het, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein Het is optionally mono- or di-substituted with R⁵ or C(O)R⁶, wherein R⁵ and R⁶ are as defined above; said Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S;~~

R³ is selected from the group consisting of: lower alkyl, lower cycloalkyl, lower alkylene, aryl or lower aralkyl, ~~all of which optionally mono- or di-substituted with:~~

~~lower alkyl, lower cycloalkyl, haloalkyl, halo, CN, azido, lower alkoxy, (lower alkyl)acyl, C₁₋₆ thioalkyl, C₁₋₆ alkylsulfonyl, NHC(O) lower alkyl, NHC(O) aryl, NHC(O) O lower alkyl, NHC(O)O aryl, aryl, aryloxy, hydroxy, nitro, amino, or Het, said Het optionally mono- or di-substituted with lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile, trifluoromethyl, C(O)R⁶ wherein R⁶ is as defined above;~~

~~said lower cycloalkyl, aryl, lower aralkyl or Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S;~~

and

R⁴ is a carboxylic acid, a salt or an ester thereof;

~~and with the provisos that:~~

~~(1) when A is benzene, R¹ is hydrogen, X and W together form a carbonyl group and Y is 4-methylphenyl, then R³ cannot be benzyl, 3-fluorophenyl, or 4-nitrophenyl;~~

~~(2) when A is benzene, R¹ is hydrogen, X and W together form a carbonyl group and R³ is cyclohexyl, then Y cannot be 4-iodophenyl or 4-methylphenyl;~~

~~(3) when A is benzene, R¹ is hydrogen, X and W together form a carbonyl group and Y is 4-fluorophenyl, then R³ cannot be 4-ethoxybenzyl;~~

~~(4) when A is benzene, R¹ is hydrogen, X and W together form a carbonyl group and Y is 2-methylphenyl then R³ cannot be 4-nitrophenyl;~~

~~(5) when A is benzene, R¹ is hydrogen, X and W together form a carbonyl group and Y is 2-methylphenyl, then R³ cannot be phenyl or 2-bromo-4-methylphenyl;~~





~~(6) when A is benzene, R¹ is hydrogen, X and W together form a carbonyl group and Y is 4-chlorophenyl, then R³ cannot be 2-methoxyphenyl or 1,3-benzodioxolyl;~~

OFFICIAL

(7) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is 4-ethylphenyl, then R^3 cannot be 3-fluorophenyl; and

(8) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is phenyl, then R^3 cannot be phenyl.

2. (currently amended) A compound selected from the group, consisting of:




wherein A, X, R^1 , Y, R^3 , and R^4 are as defined in claim 1, with the provisos indicated in claim 1.

3. (original) A mixture of compound I(a) and compound I(b), according to claim 2.

OFFICIAL

4. (original) A mixture of compound I(c) and compound I(d), according to claim 2.
5. (currently amended) A compound mixture ~~of~~, according to claim 3, wherein said mixture is racemic.
6. (currently amended) A compound mixture ~~of~~, according to claim 4, wherein said mixture is racemic.
7. (currently amended) ~~The compound I(a) and the compound I(b),~~ A compound I(a) according to claim ~~32~~, are each as a pure enantiomers.
8. (currently amended) ~~The compound I(e) and the compound I(d),~~ A compound I(c) according to claim ~~42~~, are each as a pure enantiomers.
9. (original) A compound according to claim 1 wherein X is H and W is OH; or X and W form a carbonyl group.
10. (original) A compound according to claim 9 wherein X and W form a carbonyl group.
11. (currently amended) A compound according to claim 1 wherein ring A is a benzene ring, as represented by the formula I':



wherein X, R¹, W, Y, R³, and R⁴ are as defined in claim 1, ~~with the provisos indicated in claim 1.~~

OFFICIAL

12. (cancelled)

13. (original) A compound according to claim 1, wherein R^1 is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl; or $-C(O)R^2$ wherein R^2 is lower alkyl, aryloxy or benzyloxy.

14. (original) A compound according to claim 13, wherein R^1 is H, halo or C_{1-4} alkyl.

15. (original) A compound according to claim 14, wherein R^1 is H, fluoro or methyl.


16. (original) A compound according to claim 15, wherein R^1 is H or methyl.

17. (original) A compound according to claim 1, wherein Y is phenyl optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and R^6 is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S; or Y is ethylene-phenyl, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein said phenyl ring is optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 and R^6 are as defined above; said phenyl ring being optionally fused with a saturated or unsaturated 4- to 6-membered ring optionally containing a heteroatom selected from N, O and S.

18. (original) A compound according to claim 17, wherein Y is naphthyl, $CH=CH$ -phenyl, $C(CH_3)=CH$ -phenyl or phenyl, wherein the phenyl ring is optionally mono- or di-substituted at the 3, 4, or 5 position with R^5 , wherein R^5 is halo, C_{1-4} alkyl, hydroxy, CF_3 or $NHC(O)$ -(lower alkyl).

OFFICIAL


19. (original) A compound according to claim 18, wherein Y is phenyl optionally substituted with: 3,4-Cl; 3-F,4-Cl; 3-Cl,4-F; 3,4-Br; 3-F,4-CH₃; 3,4-CH₃; 3-CF₃,



20. (original) A compound according to claim 19, wherein Y is phenyl optionally substituted with: 3,4-Cl and 3,4-Br.


21. (currently amended) A compound according to claim 1, wherein R³ is selected from the group consisting of:
cyclohexyl; C₁₋₆ alkyl; C₁₋₆ thioalkyl; (C₁₋₆ alkyl)phenyl wherein the phenyl ring is optionally substituted with:

~~lower alkyl, CF₃, halo, CN, azido, lower alkoxy, (lower alkyl)acyl, C₁₋₆ thioalkyl, C₁₋₆ alkylsulfonyl, NHC(O)-lower alkyl, aryl, aryloxy, hydroxy, nitro, amino, or Het, said Het optionally mono- or di-substituted with lower alkyl, lower alkoxy, halo, hydroxy, nitrile, or trifluoromethyl;~~




22. (currently amended) A compound according to claim 21, wherein R³ is selected from the group consisting of:

~~C₁₆-alkyl; C₁₆-thioalkyl;~~




OFFICIAL



23. (cancelled)

24. (cancelled)

















25. (currently amended) A compound selected from the group consisting of: compounds having the following formula:

















, wherein R^{4A} , R^1 , R^5 and R^3 are as defined as follows:

Cpd #	R ^{4A}	R ¹	-R ⁵	--R ³
-------	-----------------	----------------	-----------------	------------------

OFFICIAL

Cpd #	R ^{4A}	R ¹	--R ⁵	-R ³
1002	Na	—	3,4-Cl	
1003	Na	—	4-Cl	
1004	Na	—	4-Cl	
1005	Na	—	4-Cl	
1006	Na	—	4-Cl	
1007	Na	—	4-Cl	
1008	Na	—	4-iPr	
1009	Na	—	4-Cl	
1010	Na	—	4-Cl	
1011	Na	—	4-Cl	
1012	Na	—	4-Cl	
1013	Na	—	4-Cl	
1014	Na	—	4-Cl	
1015	Na	—	3-Cl	
1016	Na	—	4-CF ₃	
1017	CH ₃	—	4-Cl	

















OFFICIAL

Cpd #	R ^{4A}	R ¹	-R ³	--R ³	
1018	Na	—	3-CH ₃		;
1019	Na	a-F	4-Cl		;
1020	Na	—	3,5-Cl		;
1021	Na	—	3,4-Cl		;
1022	CH ₃	—	3,4-Cl		;
1023	Na	—	3-OCH ₃		;
1024	Na	—	3,4-CH ₃		;
1025	Na	—	3,4-Cl		;
1026	Na	—	3,4-F		;
1027	Na	—	3,4-Br		;
1028	Na	—	3,4-Cl		;
1029	Na	—	3-F, 4-Cl		;
1030	Na	—	3-Cl, 4-F		;
1031	Na	—	3-CF ₃		;

OFFICIAL

Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1032	Na	—	3-Cl	
1033	Na	—	3,4-Cl	
1034	Na	--	3,4-Cl	
1035	Na	—	3,4-Cl	
1036	Na	—	3,4-Cl	
1037	Na	b-CH ₃	3,4-Cl	
1038	Na	—	3,4-Cl	
1039	Na	—	4-Cl	
1040	Na	—	3,4-Cl	
1041	Na	d-CH ₃	3,4-Cl	
1042	Na	a-CH ₃	3,4-Cl	
1043	Na	—	3,4-Cl	
1044	Na	--	3-Cl	
1045	Na	—	3-F, 4-CF ₃	
1046	Na	—	3,4-Cl	


















OFFICIAL

Cpd #	R ^{4A}	R ^I	-R ^S	-R ^J
1047	Na	-	3,4-Cl	
1048	Na	d-F	3,4-Cl	
1049	Na	-	3,4-Cl	
1050	Na	-	3,4-Cl	
1051	Na	a-F	3,4-Cl	
1052	Na	--	3,4-Cl	
1053	Na	-	3,4-Cl	
1054	Na	-	3,4-Cl	
1055	Na	-	3,4-Cl	
1056	Na	-	3,4-CH ₃	
1057	Na	-	3,4-Cl	
1058	Na	-	3,4-Cl	
1059	Na	--	3,4-F	
1060	Na	-	3,4-Cl	
1061	Na	-	3,4-F	
1062	Na	-	3,4-F	
















OFFICIAL

Cpd #	R ^{4A}	R ¹	--R ⁵	-R ³	
1063	Na	—	3,4-Cl		±
1064	Na	—	3,4-F		±
1065	Na	—	3,4-Cl		±
1066	Na	—	3,4-Cl		±
1067	Na	—	3-F, 4-CF ₃		±
1068	Na	—	3,4-F		±
1069	Na	b-Br	3,4-Cl		±
1070	Na	—	3,4-Cl		±
1071	Na	—	3,4-CH ₃		±
1072	Na	—	3,4-Br		±
1073	Na	—	3,4-F		±
1074	Na	—	3,4-Br		±
1075	Na	—	3,4-Br		±
1076	Na	—	3,4-Br		±
1077	Na	—	3,4-Cl		±
1078	Na	—	3,4-Br		±
1079	Na	—	3,4-Br		±














OFFICIAL

Cpd #	R ^{4a}	R ¹	-R ²	-R ³	
1080	Na	—	3-CN		1/2
1081	Na	—	3,4-Br		1/2
1082	Na	—	3,4-Cl		1/2
1083	Na	—	3,4-F		1/2
1084	Na	—	3,4-Br		1/2
1085	Na	—	3-CN		1/2
1086	Na	—	3,4-Br		1/2
1087	Na	—			1/2
1088	Na	—	3,4-Br	 stereochemistry undetermined	1/2
1089	Na	—	3,4-Br	 stereochemistry undetermined	1/2
1090	Na		3,4-Cl		1/2
1091	Na		3,4-Cl		1/2
1092	Na	—	3,4-Br		1/2
1093	Na	—	3-Cl, 4-F		1/2















OFFICIAL

Cpd #	R ^{4A}	R ¹	-R ⁵	-R ⁵	
1094	Na	-	3-Cl, 4-F		$\frac{1}{2}$
1095	Na		3,4-Cl		$\frac{1}{2}$
1096	Na	-	3,4-Cl		$\frac{1}{2}$
1097	Na	-	3,4-Br		$\frac{1}{2}$
1098	Na	-	3,4-Cl		$\frac{1}{2}$
1099	Na	-	3,4-Br		$\frac{1}{2}$
1100	Na	-	3,4-Cl		$\frac{1}{2}$
1101	Na	-	3,4-Cl		$\frac{1}{2}$
1102	Na	-	3,4-Br		$\frac{1}{2}$
1103	Na	-	3,4-Br		$\frac{1}{2}$
1104	Na	-	3,4-Cl		$\frac{1}{2}$
1105	Na	-	3,4-Br		$\frac{1}{2}$
1106	Na	b-F	3,4-Cl		$\frac{1}{2}$
1107	Na	e-F	3,4-Cl		$\frac{1}{2}$











OFFICIAL

Cpd #	R ^{4a}	R ¹	-R ³	--R ³	
1108	Na	—	3,4-Cl		1/2
1109	Na	—	3,4-Br		1/2
1110	Na	—	3,4-Br		1/2
1111	Na	—	3,4-Cl		1/2
1112	Na	—	3,4-Cl		1/2
1113	Na	—	3,4-Br		1/2
1114	Na	e-Cl	3,4-Cl		1/2
1115	Na	—	3-Cl, 4-F		1/2
1116	Na	b-Cl	3,4-Cl		1/2
1117	Na	—	3,4-Cl		1/2
1118	Na	—	3,4-Br		1/2
1119	Na	—	3,4-Br		1/2
1120	Na	—	3-Cl, 4-F		1/2

OFFICIAL


Cpd #	R ^{4A}	R ¹	--R ³	--R ³	
1121	Na	—	3-Cl, 4-F		$\frac{1}{2}$
1122	Na	—	3-Cl, 4-F		$\frac{1}{2}$
1123	Na	—	3,4-Cl		$\frac{1}{2}$
1124	Na	—	3,4-Cl		$\frac{1}{2}$
1125	Na	—	3,4-Cl		$\frac{1}{2}$
1126	Na	—	3,4-Cl		$\frac{1}{2}$
1127	Na	—	3,4-Cl		$\frac{1}{2}$
1128	Na	—	3,4-Cl		$\frac{1}{2}$
1129	Na	o-OMe	3,4-Cl		$\frac{1}{2}$
1130	Na	p-OMe	3,4-Cl		$\frac{1}{2}$
1131	Na	—	3-Cl, 4-F		$\frac{1}{2}$
1132	Na	—	3,4-F		$\frac{1}{2}$
1133	Na	—	3,4-Cl		$\frac{1}{2}$
1134	Na	—	3,4-Br		$\frac{1}{2}$

OFFICIAL

Cpd #	R ^{4A}	R ¹	--R ³	--R ³	
1135	Na	—	3,4-Cl		;
1136	Na	—	3,4-Cl		;
1137	Na	—	3,4-Cl		;
1138	Na	—	3,4-Cl		;
1139	Na	—	3,4-Cl		;
1140	Na	—	3,4-Cl		;
1141	Na	—	3-NHC(O) (CH ₂) ₃ CH ₃ ; 4-Cl		;
1142	Na	—	3,5-Cl		;
1143	Na	b-F	3,4-Br		; and
1144	Na	c-F	3,4-Br		.

OFFICIAL











26. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



wherein R^{4A} , R^1 , R^5 , and R^3 are as defined as follows:


Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$
A1001	Na	--	3,4-Br	 stereochemistry undetermined
A1002	Na	--	3,4-Br	 stereochemistry undetermined
A1003	Na	mixture b-Me & c-Me	3,4-Cl	 stereochemistry undetermined
A1004	Na	b-Me	3,4-Cl	 stereochemistry undetermined
A1005	Na	c-Me	3,4-Cl	 stereochemistry undetermined
A1006	Na	mixture b-Me & c-Me	3,4-Cl	 stereochemistry undetermined

OFFICIAL









Cpd #	R ^{4A}	R ¹	--R ³	--R ³	
A1007	Na	b-Me	3,4-Cl	 stereochemistry undetermined	;
A1008	Na	c-Me	3,4-Cl	 stereochemistry undetermined	;
A1009	Na	mixture b-Me & c-Me	3,4-Br	 stereochemistry undetermined	;
A1010	Na	b-Me	3,4-Br	 stereochemistry undetermined	;
A1011	Na	c-Me	3,4-Br	 stereochemistry undetermined	;
A1012	Na	--	3,4-Br	 stereochemistry undetermined	;
A1013	Na	--	3,4-Br	 stereochemistry undetermined	;
A1014	Na	c-Me	3,4-Br		;
A1015	Na	b-F, c-Me	3,4-Br		; and
A1016	Na	b-Me, c-F	3,4-Br		.

OFFICIAL

27. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



wherein R^1 , R^2 , and R^3 are as defined as follows:


Cpd #	R^1	R^2	R^3
B1001	b-Me, c-Me (mixture)	3,4-Br	
B1002	b-Me	3,4-Br	
B1003	c-Me	3,4-Br	
B1004	b-Me	3,4-Br	
B1005	c-Me	3,4-Br	
B1006	b-Me	3,4-Br	
B1007	c-Me	3,4-Br	
B1008	b-F, c-Me	3,4-Br	

28. (cancelled)

29. (cancelled)

OFFICIAL













30. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



wherein R^5 and R^3 are as defined as follows:


Cpd #	$-R^5$	$---R^3$	
2002	4-Cl		$\frac{1}{2}$
2003	4-Cl		$\frac{1}{2}$
2004	4-Cl		$\frac{1}{2}$
2005	3-Cl		$\frac{1}{2}$
2006	4-Cl		$\frac{1}{2}$
2007	4-Cl		$\frac{1}{2}$
2008	4-CF3		$\frac{1}{2}$
2009	4-Cl		$\frac{1}{2}$
2010	4-Cl		$\frac{1}{2}$
2011	4-Cl		$\frac{1}{2}$

OFFICIAL

Cpd #	--R ⁵	--R ³	
2012	4-Cl		$\frac{1}{2}$
2013	3,4-Cl		$\frac{1}{2}$
2014	3-CH ₃		$\frac{1}{2}$
2015	4-Cl		$\frac{1}{2}$
2016	3,4-Cl		$\frac{1}{2}$
2017	4-I		$\frac{1}{2}$
2018	3,4-Cl		$\frac{1}{2}$
2019	3,4-Cl		$\frac{1}{2}$
2020	4-OH, 5-Cl		$\frac{1}{2}$
2021	3,4-Cl		$\frac{1}{2}$
2022	3,4-Cl		$\frac{1}{2}$ and
2023	3,4-Br		.

31. (currently amended) A compound selected from the group consisting of: compounds having the following formula:











OFFICIAL



wherein R¹, Y, and R³ are as defined as follows:


Cpd #	R ¹	--Y	--R ³	
3001	—			$\frac{2}{3}$
3002	—			$\frac{2}{3}$
3003	—			$\frac{2}{3}$
3004	—			$\frac{2}{3}$
3006	—			$\frac{2}{3}$
3007	—			$\frac{2}{3}$
3008	—			$\frac{2}{3}$
3009	—			$\frac{2}{3}$
3100	—			$\frac{2}{3}$
3011	—			$\frac{2}{3}$
3012	—			$\frac{2}{3}$

OFFICIAL



Cpd #	R ¹	-Y	-R ³
3013	c-Me		
3014	—		
3015	—		
3016	b-F		
3017	c-F		

Claims 32-37 (cancelled)

38. (original) A compound having the following formula:



wherein Y and R³ are as defined as follows:

Cpd #	-Y	-R ³
10,001		

39. (original) A pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I), according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

OFFICIAL

40. (currently amended) A method for treating a papillomavirus viral infection in a mammal by administering to the mammal an anti-papilloma virus virally effective amount of ~~the a compound of formula (I), according to claim 1 without the provisos indicated in claim 1,~~ or a therapeutically acceptable salt or ester thereof, or a pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1 ~~without the provisos indicated in claim 1,~~ or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

41. (currently amended) A method for inhibiting the replication of papillomavirus by exposing the virus to an amount of ~~the a compounds of formula (I), according to claim 1 without the provisos indicated in claim 1,~~ inhibiting the papilloma virus E1-E2-DNA complex, or a therapeutically acceptable salt or ester thereof, or a composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1 ~~without the provisos indicated in claim 1,~~ or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

42. (currently amended) A method of preventing perinatal transmission of HPV from mother to baby, by administering a compound of formula (I), according to claim 1, ~~without the provisos indicated in claim 1,~~ to the mother prior to giving birth.

Claims 43-53 (cancelled)

54. (new) A compound I(b) according to claim 2, as a pure enantiomer.

55. (new) A compound I(d) according to claim 2, as a pure enantiomer.